Literature DB >> 13306779

Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.

T F YU, B C PATON, T CHENKIN, J J BURNS, B B BRODIE, A B GUTMAN.   

Abstract

Entities:  

Keywords:  GOUT/therapy; KIDNEYS/effect of drugs on

Mesh：

Substances：

Year:  1956        PMID： 13306779      PMCID： PMC438822          DOI： 10.1172/JCI103288

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  11 in total

1.  Paradoxical retention of uric acid by uricosuric drugs in low dosage.

Authors:  T F YU; A B GUTMAN
Journal:  Proc Soc Exp Biol Med       Date:  1955-11

2.  The effect of phenylbutazone on uric acid metabolism in two normal subjects.

Authors:  J B WYNGAARDEN
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

3.  Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout.

Authors:  A B GUTMAN; T F YU; V RANDOLPH
Journal:  Trans Assoc Am Physicians       Date:  1954

4.  Current principles of management in gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1952-12       Impact factor: 4.965

5.  Ultrafiltrability of plasma urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  Proc Soc Exp Biol Med       Date:  1953-10

6.  Phenylbutazone (butazolidin) in gout.

Authors:  W C KUZELL; R W SCHAFFARZICK; W E NAUGLER; G GAUDIN; E A MANKLE; B BROWN
Journal:  Am J Med       Date:  1954-02       Impact factor: 4.965

7.  The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.

Authors:  J J BURNS; R K ROSE; T CHENKIN; A GOLDMAN; A SCHULERT; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1953-11       Impact factor: 4.030

8.  Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.

Authors:  T F YU; J H SIROTA; A B GUTMAN
Journal:  J Clin Invest       Date:  1953-11       Impact factor: 14.808

9.  The metabolic fate of phenylbutazone (butazolidin) in man.

Authors:  J J BURNS; R K ROSE; S GOODWIN; J REICHENTHAL; E C HORNING; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1955-04       Impact factor: 4.030

10.  Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione).

Authors:  B B BRODIE; T F YU; J J BURNS; T CHENKIN; B C PATON; J M STEELE; A B GUTMAN
Journal:  Proc Soc Exp Biol Med       Date:  1954 Aug-Sep
View more
  3 in total

1.  Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents.

Authors:  A B GUTMAN; T F YU
Journal:  Bull N Y Acad Med       Date:  1958-05

3.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.